&Partners Acquires Shares of 2,381 Cencora, Inc. (NYSE:COR)

&Partners bought a new stake in Cencora, Inc. (NYSE:COR) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,381 shares of the company’s stock, valued at approximately $579,000.

Other institutional investors have also modified their holdings of the company. Rise Advisors LLC purchased a new position in Cencora in the 1st quarter valued at $25,000. CVA Family Office LLC purchased a new stake in shares of Cencora in the first quarter valued at about $34,000. Bruce G. Allen Investments LLC acquired a new position in shares of Cencora during the first quarter worth about $43,000. Trust Co. of Vermont purchased a new position in Cencora during the fourth quarter worth about $62,000. Finally, Tompkins Financial Corp acquired a new stake in Cencora in the first quarter valued at about $122,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the sale, the insider now directly owns 24,418,171 shares of the company’s stock, valued at $5,252,836,945.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Cencora news, EVP Gina Clark sold 1,874 shares of the company’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $223.86, for a total transaction of $419,513.64. Following the completion of the sale, the executive vice president now directly owns 13,284 shares in the company, valued at $2,973,756.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of Cencora stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now directly owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The disclosure for this sale can be found here. Insiders sold a total of 1,956,675 shares of company stock valued at $422,352,056 in the last 90 days. 15.80% of the stock is currently owned by insiders.

Cencora Price Performance

Shares of NYSE:COR opened at $236.68 on Monday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The business’s fifty day moving average price is $229.50 and its two-hundred day moving average price is $227.07. The stock has a market cap of $47.21 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 1.64 and a beta of 0.48. Cencora, Inc. has a one year low of $171.65 and a one year high of $246.75.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.65 by $0.15. The business had revenue of $68.41 billion for the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.50 earnings per share. On average, analysts forecast that Cencora, Inc. will post 13.44 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were issued a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is 22.32%.

Analysts Set New Price Targets

COR has been the topic of a number of analyst reports. Leerink Partnrs restated an “outperform” rating on shares of Cencora in a research note on Monday, February 26th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Robert W. Baird boosted their price objective on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. SVB Leerink assumed coverage on shares of Cencora in a report on Monday, February 26th. They issued an “outperform” rating and a $261.00 target price for the company. Finally, Citigroup boosted their price target on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $233.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.